Insider News
Latest Issue
Current Issue
Featured Report
Process Intensification: Overcoming the Inefficiencies of Traditional Fed Batch in Upstream Cell Culture
BioProcess Insider Daily - Biotech Week Boston
Read More
Aurigene’s chief commercial officer says his firm and other Indian CDMOs are “a very viable alternative” if major Chinese manufacturers are removed from the US biopharma supply chain.
Cell therapies will play an increasingly important position in AstraZeneca’s broad oncology pipeline, an SVP told delegates at Biotech Week Boston (BWB) last month.
Smaller innovators are more likely to be upended by US legislation aimed at restricting working with China-based CDMOs like WuXi Biologics, according to Latham Biopharm.
Vertex says finding the sweet spot in manufacturing capacity is key to ensuring the successful rollout of sickle cell gene therapy Casgevy (exagamglogene autotemcel).
Latest eBooks
See All
Special Reports
As the monoclonal-antibody (mAb) market continues to grow, it is becoming increasingly important for pharmaceutical and biotech companies to accelerate process development and establish a scalable manufacturing process capable of achieving high titers and consistent product quality. Central to this is a cell culture media and feed system that can provide the required nutrients for optimal cell growth, viability, and function, as well as facilitate a seamless transition from development to clinical and commercial manufacturing. However, choosing an appropriate system can be a complex and time-consuming process, often requiring the evaluation of multiple medium and feed options. Platform systems, consisting of a medium and complementary feed developed for a specific cell line and application, have emerged as a valuable option for developers to help simplify selection and increase scale-up efficiency. To meet the need for high-performance platform mAb manufacturing solutions, Thermo Fisher Scientific has dev...
Precision in volume delivery is critically important for both the biopharmaceutical and medical device industries. This special report discusses how accurate volume measurement affects patient safety, product quality, and regulatory compliance. Sartorius emphasizes the roles that infusion pumps, laboratory pipettes, and quality control (QC) measures play in ensuring reliable and reproducible results. Register or Login and hit Download Now to get the full Special Report.
Ask the Expert Webcasts
This webcast features: Sanjay Kumar, PhD, head of technical excellence, media solutions, Lonza Bioscience Media Solutions. The growing field of antibody therapeutics is revolutionizing healthcare by offering more precise treatments for various diseases. This advancement demands that pharmaceutical companies efficiently produce high-quality proteins in large volumes. The TheraPRO® CHO Media System, an advanced formulated, chemically defined, and animal component-free media system, meets this need. Designed for ease of use, it maximizes protein production while ensuring high quality compared to leading competitor CHO media systems. It also ensures scalability and consistency across different production scales, enabling a seamless transition from research to commercial manufacturing. This innovation supports the industry’s goal to deliver effective treatments more quickly and reliably. In this webinar, Sanjay Kumar, PhD will discuss Lonza’s CHO media portfolio, with a focus on the TheraPRO® GS CHO media ...
This webcast features: James Humphrey, research and technology specialist, Garima Sinha, lead applications scientist, & Jessica Santa Maria, technical marketing lead, Croda Pharma. Poloxamer 188 is a surfactant with a longstanding history of use in pharmaceutical drugs, spanning dosage routes from oral to topical and parenteral administration. In the biomanufacturing space, it finds application not only as a surfactant for parenteral biological formulations, but also in cell culture as a shear stress protectant. Its specific surfactant properties make it effective at stabilizing proteins, as well as protecting cells from shear stress caused by agitation in a bioreactor. Poloxamer 188 has the ability to prevent cell shear stress due to its specific balance of hydrophobic PPO chain flanked by two blocks of hydrophilic PEO. However, impurities from the manufacturing process can compromise its performance, leading to detrimental effects on cell health and contributing to batch-batch inconsistency. On...
.png?width=300&auto=webp&quality=80&disable=upscale)
